Regulation of gene expression in the nervous system by Ooi, Lezanne & Wood, Ian C
University of Wollongong 
Research Online 
Faculty of Science - Papers (Archive) Faculty of Science, Medicine and Health 
2008 
Regulation of gene expression in the nervous system 
Lezanne Ooi 
University of Wollongong, lezanne@uow.edu.au 
Ian C. Wood 
University of Leeds, i.c.wood@leeds.ac.uk 
Follow this and additional works at: https://ro.uow.edu.au/scipapers 
Recommended Citation 
Ooi, Lezanne and Wood, Ian C.: Regulation of gene expression in the nervous system 2008, 327-341. 
https://ro.uow.edu.au/scipapers/4647 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Regulation of gene expression in the nervous system 
Abstract 
The nervous system contains a multitude of cell types which are specified during development by 
cascades of transcription factors acting combinatorially. Some of these transcription factors are only 
active during development, whereas others continue to function in the mature nervous system to maintain 
appropriate gene-expression patterns in differentiated cells. Underpinning the function of the nervous 
system is its plasticity in response to external stimuli, and many transcription factors are involved in 
regulating gene expression in response to neuronal activity, allowing us to learn, remember and make 
complex decisions. Here we review some of the recent findings that have uncovered the molecular 
mechanisms that underpin the control of gene regulatory networks within the nervous system. We 
highlight some recent insights into the gene-regulatory circuits in the development and differentiation of 
cells within the nervous system and discuss some of the mechanisms by which synaptic transmission 
influences transcription-factor activity in the mature nervous system. Mutations in genes that are 
important in epigenetic regulation (by influencing DNA methylation and post-translational histone 
modifications) have long been associated with neuronal disorders in humans such as Rett syndrome, 
Huntington's disease and some forms of mental retardation, and recent work has focused on unravelling 
their mechanisms of action. Finally, the discovery of microRNAs has produced a paradigm shift in gene 
expression, and we provide some examples and discuss the contribution of microRNAs to maintaining 
dynamic gene regulatory networks in the brain. 
Keywords 
expression, regulation, gene, system, nervous, CMMB 
Publication Details 
Ooi, L. & Wood, I. C. (2008). Regulation of gene expression in the nervous system. Biochemical Journal, 
414 (3), 327-341. 
This journal article is available at Research Online: https://ro.uow.edu.au/scipapers/4647 
Biochem. J. (2008) 414, 327–341 (Printed in Great Britain) doi:10.1042/BJ20080963 327
REVIEW ARTICLE
Regulation of gene expression in the nervous system
Lezanne OOI and Ian C. WOOD1
Institute of Membrane and Systems Biology, Faculty of Biological Sciences, Garstang Building, University of Leeds, Leeds LS2 9JT, U.K.
The nervous system contains a multitude of cell types which
are specified during development by cascades of transcription
factors acting combinatorially. Some of these transcription factors
are only active during development, whereas others continue to
function in the mature nervous system to maintain appropriate
gene-expression patterns in differentiated cells. Underpinning
the function of the nervous system is its plasticity in response
to external stimuli, and many transcription factors are involved
in regulating gene expression in response to neuronal activity,
allowing us to learn, remember and make complex decisions.
Here we review some of the recent findings that have uncovered
the molecular mechanisms that underpin the control of gene
regulatory networks within the nervous system. We highlight
some recent insights into the gene-regulatory circuits in the
development and differentiation of cells within the nervous
system and discuss some of the mechanisms by which synaptic
transmission influences transcription-factor activity in the mature
nervous system. Mutations in genes that are important in
epigenetic regulation (by influencing DNA methylation and post-
translational histone modifications) have long been associated
with neuronal disorders in humans such as Rett syndrome,
Huntington’s disease and some forms of mental retardation, and
recent work has focused on unravelling their mechanisms of
action. Finally, the discovery of microRNAs has produced a
paradigm shift in gene expression, and we provide some examples
and discuss the contribution of microRNAs to maintaining
dynamic gene regulatory networks in the brain.
Key words: chromatin, gene expression, microRNA, nervous
system, synaptic plasticity, transcription.
INTRODUCTION
The brain is the most complex organ in the human body, con-
taining the largest diversity of cell types of any organ. Collect-
ively, cells that form the nervous system express 80% of genes
in the genome [1]. However, each individual cell type expresses
a distinct subset of those genes. Preservation of appropriate ex-
pression of these genes is a highly regulated process during devel-
opment to ensure production of correct numbers of the different
cell types and to maintain essential neuronal signalling pathways.
Complexity within the brain continues into adulthood, and cells
undergo phenotypic changes in response to environmental cues
and neuronal signalling. Such plasticity is vital and underlies our
higher cognitive functions, such as learning and memory.
Development of the nervous system is brought about by waves
of transcription factors, which act combinatorially to specify
neural gene networks and determine cell fate. Many of these
transcription factors are not expressed in the adult brain; rather,
they wield their power during development, bringing about lasting
gene-expression changes that extend into adulthood. Nevertheless
a substantial number of transcription factors are expressed in
the brain and are vital for regulating phenotypic plasticity by
controlling expression of a multitude of genes. It is now well
established that alterations in gene expression are important in
learning and memory, and also that inappropriate regulation of
gene expression is a cause of a multitude of neuronal diseases.
Though many mechanisms that control gene expression in neurons
have been uncovered, there is still much work to be done before we
fully understand how these individual mechanisms are integrated
and feed into neuronal gene networks to create a complex organ
that maintains homoeostatic control of our bodies, allows us
to interpret our environment and to make complex decisions.
Here we review some of the recent advances that have been
made in elucidating the mechanisms that regulate neuronal gene
expression and highlight the insights that have contributed to our
understanding of the progression of neuronal disease.
Abbreviations used: AA-NAT, acylalkalamine N-acetyltransferase; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ATRX, α-
thalassaemia/mental retardation, X-linked; BMP, bone morphogenetic protein; Bdnf, BDNF (brain-derived neurotrophic factor) gene; bHLH, basic
helix–loop–helix; BRAF35, BRCA2-associated factor 35; Calb1, calbindin gene; CaMKIV, calmodulin kinase IV; Cdk1, cyclin-dependent kinase 1; CK1,
casein kinase-1; CREB, cAMP-response-element-binding protein; CBP, CREB-binding protein; CCAT, calcium-channel-associated transcription regulator;
CCR, C–C chemokine receptor; ChIP, chromatin immunoprecipitation, CREM, cAMP-responsive-element modulator; DNMT, DNA methyltransferase; DRE,
downstream regulatory element; DREAM, downstream- regulatory-element antagonistic modulator; DRG, dorsal root ganglion; DSCR1, Down syndrome
critical region gene 1; DYRKIA, dual-specificity tyrosine-phosphorylation-regulated kinase 1A; ERK, extracellular-signal-regulated kinase; ES, embryonic
stem; ESET, ERG (ets-related gene)-associated protein with SET (suppressor of variegation, enhancer of zest and trithorax) domain; FGF, fibroblast
growth factor; FMRP, fragile X mental retardation protein; FOXO1, forkhead box O1; GABA, γ-aminobutyric acid; Gadd45a, growth arrest and DNA-
damage-inducible 45 alpha; GluR2, glutamate receptor subunit 2; Gria2, glutamate receptor, ionotropic, AMPA2; GSK3, glycogen synthase kinase 3;
H3K4, histone H3 Lys4 (etc.); HAT, histone acetyltransferase; HDAC, histone deacetylase; HEK-293, human embryonic kidney-293; ICER, inducible cAMP
repressor; IP3R1, Ins(1,4,5)P3 receptor type 1; JARID1C, jumonji, AT-rich interactive domain 1C; Lmtk1, lemur tyrosine kinase 1; LSD, lysine-specific
demethylase; LTP, long-term potentiation; MBD2, methyl-CpG-binding domain protein 2; MeCP2, methyl-CpG binding protein 2; mEPSC, miniature
excitatory postsynaptic current; MKP, MAPK (mitogen-activated protein kinase) phosphatase; MSK, mitogen- and stress-activated kinase; MLL, mixed-
lineage leukaemia; MOR1, μ-opiod receptor; NFAT, nuclear factor of activated T-cells; NMDA, N-methyl-D-aspartate; KChIP, potassium channel-interacting
protein; PI3K, phosphoinositide 3-kinase; PP1, protein phosphatase 1; PTBP, polypyrimidine-tract-binding protein; Ptf1a, pancreas-specific transcription
factor 1a; REST, repressor element 1-silencing transcription factor; SCA, spinocerebellar ataxia; TDG, thymine-DNA glycosylase; TORC, transducer of
regulated CREB activity; VMN, visceral motor neuron.
1 To whom correspondence should be addressed (email i.c.wood@leeds.ac.uk).
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DEVELOPMENT AND DIFFERENTIATION
Cells in the nervous system arise from ES (embryonic stem) cells
that develop into neural stem cells that, in turn, differentiate into
neurons, astrocytes or oligodendrocytes. Many groups have now
identified a core regulatory network of the transcription factors
Nanog/Sox2/Oct4 that is important for controlling pluripotency
and self-renewal of ES cells (reviewed in [2]). Combinatorially
these transcription factors regulate their own expression levels
in addition to those of many other genes, and disruption of
any component of the network is sufficient to disrupt the
whole system. Once initiated, this circuit is self-maintaining,
and differentiation of ES cells toward specific cell fates requires
external signalling via secreted molecules such as BMP (bone
morphogenetic protein). Nanog is critical for maintaining the ES
cell state. The expression of Nanog fluctuates in ES cells over
time and, when levels of Nanog are low, ES cells are predisposed
to cell differentiation [3]. Thus low levels of Nanog provide a
window of opportunity for ES cell differentiation that is lost
when the levels of Nanog subsequently rise [3]. Sox2 expression
is important for maintaining Oct4 levels. In the absence of Sox2,
other Sox proteins expressed in ES cells, such as Sox4, 11 and
15, can co-operate with Oct4 to activate expression of target
genes, including Oct4 itself [4]. However, loss of Sox2 results in
reduced expression of the gene Nr5a2 (nuclear receptor subfamily
5, group A, member 2), which encodes a steroid hormone receptor
that activates Oct4 expression, and increased expression of Nr2f2
(nuclear receptor subfamily 2, group F, member 2), which encodes
a steroid hormone receptor that represses Oct4 expression. Thus
despite the ability of Sox4, 11 and 15 to substitute for Sox2 and
directly enhance Oct4 expression, loss of Sox2 leads to reduced
Oct4 levels and ES cell differentiation. In ES cells that lack Sox2,
it is the effect on Oct4 levels that are crucial, as highlighted by the
fact that ectopic expression of Oct4 is sufficient to prevent ES-
cell differentiation [4]. Oct4 appears to play a more general role
than either Sox2 or Nanog. In co-operation with Sox2 and Nanog,
Oct4 binds to and regulates the expression of many genes. Unlike
Nanog, Oct4 levels do not appear to fluctuate, and redundancy
among Oct factors has not been identified. ES cells become
committed to neural cell lineages and differentiate toward specific
neuronal or glial cell fates in response to a range of signals,
including retinoic acid, FGF (fibroblast growth factor), inhibition
of BMP signalling, and Notch and Wnt signalling [5]. Cell
fate specification towards either neural-stem-cell maintenance or
differentiation toward post-mitotic neurons or glia is achieved
through a balance of antagonistic transcription factors [6,7].
Transcription factors play a key role in specifying neuronal
identity upon neuronal differentiation, and much work has been
undertaken in an attempt to understand the transcription-factor
network that defines specific neuronal lineages. Combinations
of transcription factors result in different, but specific, cell
fates. The co-ordinated function of homoeodomain and bHLH
(basic helix–loop–helix) transcription factors, including Mash1,
neurogenin and Math1, are involved in differentiation of neural
progenitors into neurons and specification of neuronal subtype
[6]. Most neurons differentiate toward either a glutamatergic
(excitatory neuron) or GABAergic (inhibitory neuron; GABA is
γ -aminobutyric acid) phenotype, and the actions of a range of
transcription factors have been implicated in implementing this
decision in different regions of the nervous system. Expression
of the bHLH gene Mash1 promotes generation of GABAergic
neurons from neural stem cells of the subependymal zone [8],
whereas the bHLH transcription factor Ptf1a (pancreas-specific
transcription factor 1a) [as a heterodimer with RBJ (rab- and
DnaJ-domain containing) protein] defines GABAergic neurons in
the cerebellum [9]. In the absence of Ptf1a, only glutamatergic
neurons are formed in the cerebellum, whereas ectopic expression
of Ptf1a in glutamatergic precursors is sufficient to switch neurons
to the GABAergic phenotype [10]. The homoeobox containing
transcription factors Tlx1 and Tlx3 promote specification of
glutamatergic neurons, inhibit GABAergic differentiation in
spinal-cord neurons [11] and antagonize the functions of
Lbx1, which promotes GABAergic differentiation [12]. Lbx1 is
expressed in glutamatergic neurons, but its actions to promote
GABAergic differentiation are inhibited by the expression of
Tlx1 and Tlx3. Mice lacking Tlx3 show increased GABAergic
differentiation, which is due to the presence of Lbx1, but
interestingly, normal glutamatergic differentiation is restored in
mice that lack both Tlx3 and Lbx1 [12].
Transcription factors operate combinatorially and can promote
different cell fates as a result of interactions with other
transcription factors in specific cells. Neurogenin2 expression in
the forebrain promotes the generation of glutamatergic neurons
[13] and in the spinal cord in association with Olig2, promotes
motor-neuron differentiation [14]. Combinations of Pax6, Olig2
and Nkx2.2 and their inhibitors, Id and Hes, define both
neuronal, and then glial, differentiation [7], while Dlx1 and Dlx2
promote neurogenesis by inhibiting Olig2 in mouse forebrain
progenitors [15]. Transcription factors such as Pax6, Olig2 and
Nkx2.2 can also act combinatorially in specifying cell fate towards
motor neurons, oligodendrocytes and dopaminergic neurons
[16–18]. Nkx2.2 promotes differentiation toward serotonergic
neurons [19], whereas Olig2 promotes a motor-neuron fate
[20]. In fact Nkx2.2 and Olig2 function antagonistically, and
both transcription factors repress each other’s expression during
the differentiation process [16]. Though many such mutually
antagonistic relationships between individual transcription factors
are known, the complete identification of all target genes for
a particular factor during development has not been carried
out. Such information, though technically challenging to obtain,
would provide the first steps towards really understanding
the transcription-factor networks that specify the multitude of
neuronal cell types.
The timing of transcription-factor activity is important during
the generation of many cell types; neuronal subtypes are often
produced sequentially from the same pool of multipotent progeni-
tors. One such example is found in the hindbrain, where VMNs
(visceral motor neurons) and serotonergic neurons are gene-
rated sequentially from the same set of progenitor cells [21].
This mechanism requires the actions of two transcription factors,
Phox2b and Mash1, that are required for VMN and seroto-
nergic differentiation respectively. Foxa2 is also required for
serotonergic specification and, as with Nkx2.2 and Olig2, Foxa2
and Phox2b mutually repress each other’s expression [21]. The
activity of Phox2b dominates that of Foxa2, meaning that initially
VMNs are produced and a switch to serotonergic differentiation
is initiated only by increased expression of Foxa2 [21] through an
unidentified mechanism. The increased levels of Foxa2 repress
expression of Phox2b and activate serotonergic differentiation.
Foxa2 therefore acts as a key molecular switch and in its absence,
serotonergic neurons are not produced.
In addition to roles in guiding neuronal progenitors toward
specific neuronal fates, other transcription factors are important
for regulating more general aspects of neuronal phenotype.
One such transcription factor is the REST [repressor element
1-silencing transcription factor, also known as NRSF (neural
restrictive silencer factor)]. Reduced expression of the transcrip-
tional repressor REST is an important step in neuronal differ-
entiation. REST is expressed in ES cells [22–24], and down-
regulation of REST is required prior to neuronal differentiation
c© The Authors Journal compilation c© 2008 Biochemical Society
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[22,24,25]. Removal of mitogens and addition of retinoic acid
to cultures of ES cells results in loss of REST expression
both by reduced mRNA levels and enhanced targeting of REST
protein for degradation and a concomitant differentiation of cells
into neurons [22,24,26]. REST can recruit multiple chromatin-
modifying enzymes via interactions with at least two independent
co-repressor complexes containing mSin3 and CoREST [27–29]
(for a recent review on chromatin and REST, see [30]), which are
utilized to repress its predicted 1800 target genes [31,32]. Many
of these genes are normally expressed in differentiated neurons
and are important for neuronal functions such as neurotransmitter
release [24,33–35] and axon guidance [36].
The exact role of REST repression in defining neuronal gene
expression is still not entirely clear, though it is able to contribute
to the deposition of epigenetic marks in neuronal genes, and
these effects persist even after REST expression is lost. Indeed,
loss of REST from promoters of some genes during neuronal
differentiation does not lead to their immediate de-repression and
the CoREST–MeCP2 (methyl-CpG binding protein 2) complex
recruited by REST may remain bound to the promoter [22]. In
this way repression of Calb1 (calbindin) and Bdnf [BDNF (brain-
derived neurotrophic factor)] genes is maintained until released
by other events, such as membrane depolarization, which results
in MeCP2 phosphorylation and/or DNA demethylation, loss of
MeCP2 binding and gene activation [22].
Thus, during development and differentiation, combinatorial
actions of transcription factors regulate specification of neural-
cell type as well as the acquisition of general features associated
with the neuronal phenotype. Appropriate control of gene
regulation remains important in the mature nervous system, the
difference being that the outcomes of gene regulation switch from
specification and differentiation to regulating gene expression in
response to neuronal activity.
GENE EXPRESSION CHANGES IN RESPONSE TO NEURONAL
ACTIVITY
Neuronal activity results in the influx of calcium and a rise in
intracellular calcium levels in neurons. Influx of calcium and
changes in the intracellular calcium levels influence the function
of several transcription factors (Figure 1).
CREB (cAMP response element binding protein)
CREB is a key modulator in regulating gene expression programs
in response to neuronal activity and is pivotal in mediating long-
term memory and synaptic plasticity [37]. Neuronal activity and
calcium entry through synaptic NMDA (N-methyl-D-aspartate)
receptors results in phosphorylation of CREB at Ser133 and
recruitment of the transcriptional co-activator CBP (CREB-
binding protein) [38]. Transcriptional activation is also regulated
by phosphorylation of CBP by CaMKIV (calmodulin kinase IV),
and CBP activates transcription via its intrinsic HAT (histone
acetyltransferase) activity [39]. Another co-activator of CREB
is TORC (transducer of regulated CREB activity). There are
three members of the TORC family encoded by individual genes,
one of which (TORC1) is expressed in neurons [40]. TORC1
can interact with CREB independently of the phosphorylation
status of Ser133 and potentiates CREB-mediated transcriptional
activation and is required for LTP (long-term potentiation) in
hippocampal neurons [40] (LTP is the process whereby communi-
cation between two neurons is strengthened as a result of both
neurons being active at the same time. The effects are long-
lasting and are mediated by increased neurotransmitter signalling
Figure 1 Neuronal activity and calcium influx regulate the function of
several transcription factors in neurons
Depolarization of neurons results in the entry of Ca2+ through voltage-gated calcium channels
such as Cav1.2, whereas glutamate stimulates NMDA receptor activation and Ca2+ influx
through NMDA receptors of depolarized neurons. Increased intracellular calcium has many
effects and underlies many neuronal responses to synaptic activity. Of particular relevance
to the present review are: (i) the phosphorylation of CREB, which results in recruitment of
CBP and activation of CREB responsive genes; (ii) the activation of the protein phosphatase
calcineurin, which dephosphorylates NFAT, allowing NFAT to enter the nucleus, bind to DNA
and regulate transcription; (iii) the inhibition of the cleavage of Cav1.2, which prevents
the cleaved C-terminal region CCAT from moving to the nucleus to regulate transcription.
An animated version of this Figure can be found at http://www.BiochemJ.org/bj/414/0327/
bj4140327add.htm.
between the two neurons. LTP is thought to be a good candidate for
the molecular mechanism that underlies memory formation). The
requirement for TORC1 in LTP provides another layer of CREB
regulation, because TORC1 is normally located in the cytoplasm
and translocates to the nucleus in response to phosphorylation
by an unidentified kinase. Both calcium entry (through NMDA
receptors or voltage-gated calcium channels) and stimulation of
cAMP is required for phosphorylation of TORC1 and transcrip-
tional activation by CREB [41]. Thus TORC1 acts as a coincid-
ence detector for activity, neither calcium entry nor increased
cAMP levels alone being sufficient to stimulate activity.
One of the most well-studied targets of CREB transcriptional
activation is BDNF, whose identification provided the first insights
into the mechanisms by which CREB activation could modulate
synaptic activity and neuronal survival [42]. The subsequent
availability of complete genome sequences has allowed a more
holistic approach in trying to predict the response to CREB activ-
ity. Although a genome-wide analysis to identify CREB target
genes in neurons has not yet been performed, data from several
other cell types can shed light on the gene targets and mechan-
isms of action of CREB. Using a genome-wide ChIP–SACO
(chromatin immunoprecipitation–serial analysis of chromatin
occupancy) technique, Impey et al. [43] identified 6302 sites
that were bound by CREB in the rat pheochromocytoma cell
line PC12. In a separate study, Zhang et al. [44] used a ChIP
microarray analysis in HEK-293 (human embryonic kidney-293)
cells and predicted that CREB is bound at approx. 4000 sequences,
on the basis of their observations of 2811 bound promoters
from a selection of 16000 genes. Binding of CREB to genes
does not appear to be regulated by its phosphorylation status. It
would appear that at most promoters CREB is phosphorylated
c© The Authors Journal compilation c© 2008 Biochemical Society
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in response to increased cAMP; however, CBP is recruited, and
transcription is activated, at only a subset of those genes [44].
Given the wide-ranging roles of CREB outside as well as within
the nervous system, it is not surprising that it has the potential
to regulate such a large number of genes. The evidence would
suggest that it is the recruitment of CBP that dictates which
CREB-regulated genes are responsive in any particular cell type.
Although CBP recruitment is known to require phosphorylation
of Ser133 in CREB there must be additional mechanisms (perhaps
further cofactor interactions) that are also required for CBP
recruitment in vivo, as increased cAMP can increase Ser133
phosphorylation but not CBP recruitment to all CREB-bound
genes [44].
CCAT (calcium-channel-associated transcription regulator)
As previously highlighted, influx of calcium is pivotal for activ-
ity-dependent changes in neuronal gene expression. The L-type
voltage-gated calcium channel Cav1.2 contributes to this mechan-
ism by its ability to allow calcium into the cell but, in addition, a
region of its C-terminus can also be cleaved to create a transcrip-
tion factor (Figure 1). CCAT is a 75 kDa protein which is the
product of cleavage of the C-terminus of the Cav1.2 channel [45].
The cleavage has been characterized in a subset of inhibitory
(GABAergic, GAD65-positive) neurons in the rat cortex and
the peptide produced translocates to the nucleus. Within the
nucleus, CCAT binds to the nuclear protein p54(nrb)/NonO,
associates with gene promoters and activates the expression
of some target genes such as Gjb5 (connexin 31.1) and Ntn4
(netrin4), while it repress the expression of other genes such as
Trpv4 (transient receptor potential vanilloid-4) and Kcnn3
(potassium intermediate/small conductance calcium-activated
channel, subfamily N, member 3). In fact many of the genes regu-
lated by CCAT encode proteins that play a role in neuronal excit-
ability, thereby providing another mechanism by which neuronal
depolarization results in a remodelling event that impacts upon
future activity [45]. Calcium entry through Cav1.2 or NMDA,
but not AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazoleprop-
ionic acid) receptors, was shown to promote relocalization of
CCAT from the nucleus to the cytoplasm. Such relocalization
of CCAT is inhibitory, as it prevents its ability to influence
transcription. The in vivo function of CCAT is not clear, though
there is some evidence to support a role for regulation of the
neuronal cytoskeleton, suggesting it may play a role in modulating
neuronal connectivity. When expressed in HEK-293 cells [46] and
in Purkinje neurons [47], the P/Q voltage-gated calcium channel
Cav2.1 is also cleaved and produces a 74 kDa proteolytic fragment
constitutively, which accumulates in the nucleus. The truncated
fragment contains the polymorphic CAG repeat region, expansion
of which is responsible for SCA6 (spinocerebellar ataxia type 6),
and fragments containing expanded CAG repeats are toxic and
result in cell death. Though there is no evidence that toxicity
is mediated via changes in gene expression, such a mechanism
would be consistent with proposed mechanisms of toxicity of
CAG expansions in other types of SCAs such as SCA1 [48,49]
and neurodegenerative diseases such as Huntington’s disease [50].
Cleavage of another L-type calcium channel, Cav1.3, is stimulated
by calcium entry through NMDA receptors and appears to produce
a channel with increased flow of calcium [51]. Whether the
proteolytic fragment may also function as a transcription factor, or
whether its loss is only required for altering Cav1.3 properties, has
not been studied. Other examples of membrane proteins that are
cleaved to produce transcription factors include PKD1 (polycystic
kidney disease 1) [52] and the APP (β-amyloid precursor protein)
[53].
NFAT (nuclear factor of activated T-cells)
NFAT proteins were originally identified as transcription factors
that promote expression of target genes in response to activation
of immune cells [54]. However, in actuality they are expressed in
many cell types, including neurons. NFATc proteins shuttle to and
from the nucleus as a consequence of their phosphorylation status,
which is altered in response to changes in intracellular calcium
levels. Phosphorylated NFATc is retained in the cytoplasm and is
inactive. Increases in intracellular calcium activate the calcium
binding phosphatase calcineurin, which dephosphorylates and
activates NFATc, causing it to translocate to the nucleus, where-
upon it up-regulates target gene expression (Figure 1). However,
activation of NFATc can also repress expression of target genes in
other systems. For example, in mouse cardiomyocytes, activated
NFAT results in reduced expression of the potassium channel
gene Kcnd2 that encodes Kv4.2 [55]. However, whether this is a
direct effect of NFATc is not clear. Nuclear NFAT is inactivated
by phosphorylation by the kinases CK1 (casein kinase 1) [56] and
GSK3 (glycogen synthase kinase 3) [57]. There are four members
of the family, NFATc1–NFATc4, which have functions in many
regions of the brain. NFATc is activated in hippocampal neurons in
response to neuronal signalling [57], in superior cervical ganglion
neurons by repetitive action potentials [58], in spinal neurons by
substance P or neurotrophins [59,60] and in developing cochlear
neurons by de-afferentation [61] or cocaine [62]. Just as the stimuli
for NFAT activation are varied, so are the functional outcomes,
which include neuronal survival [60], neuronal death [61] and
pain-sensitivity [63].
In mouse striatal neurons, stimulation of dopamine D1 receptors
activates NFATc4 via calcium entry through L-type calcium
channels [62]. Two potential targets for activated NFATc4 are
IP3R1 [Ins(1,4,5)P3 receptor type 1] and GluR2 (glutamate
receptor subunit 2), both of which can be activated by nuclear
NFATc4 and show increased mRNA levels after dopamine-
receptor activation [62]. The dopamine receptor signalling path-
way is important in the development of addiction, particularly
the addiction to some drugs of abuse, such as cocaine [64].
Exposure of mice to repeated, but not a single, injection of cocaine
over a 5-day period resulted in enhanced nuclear localization
of NFATc4 in striatal neurons and an approx. 2-fold increased
expression of IP3R1 and GluR2 mRNA [62]. Increased expression
of these genes should result in enhanced synaptic transmission,
and thus NFATc4 activation may underlie some of the gene-
expression changes that play a role in the remodelling of neuronal
transmission mediated by repeated exposure to addictive drugs.
Interestingly, although increased IP3R1 expression is mediated
via NFAT activation in striatal neurons [62] and hippocampal
neurons [60], in spinal neurons increased IP3IR expression occurs
independently of NFAT activation [63].
NFATc1–NFATc4 genes are all expressed in rat DRG (dorsal
root ganglion) neurons, and NFAT activation induced the
expression of the CCR2 and CCR5 (C–C chemokine receptors
type 2 and 5) in DRG neurons in response to depolarising stimuli
[65]. Increased expression of CCR2 in neurons has been linked to
the development of allodynia and neuropathic pain [66] (allodynia
is a painful response to a normally non-painful stimulus. It is
the result of the increased sensitivity and excitability of sensory
neurons. Neuropathic pain is a chronic pain resulting from some
problem within the neuron. Unlike nociceptive pain, in which
neurons send pain signals to the brain in response to tissue
damage, in neuropathic pain the signal is generated within the
neurons themselves). The stimulation of CCR2 expression by
NFAT activation is likely to be direct, as the CCR2 promoter
region contains an evolutionary conserved NFAT-binding site
c© The Authors Journal compilation c© 2008 Biochemical Society
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which is required for activation by NFAT [65]. Increased Cox2
(cyclo-oxygenase 2) expression is also associated with pain and
in spinal neurons increased Cox2 mRNA levels are dependent on
NFATc activation [63].
Down’s syndrome is the most common cause of mental
retardation and results in major developmental defects that affect
the face, heart and gastrointestinal tract, among others. It results
from a trisomy of chromosome 21, and the perturbation of NFAT
signalling makes a significant contribution to the phenotype.
Increased expression of the genes encoded within a critical region
of chromosome 21, covering about 3 Mb, can replicate all of
the facial features of Down’s syndrome and two of the genes
within this region negatively regulate NFATc activity. Expression
of DSCR1 (Down syndrome critical region gene 1) is higher in
foetuses of Down-syndrome patients and interacts directly with
calcineurin, inhibiting its function and reducing activation of
NFATc [67]. A second gene, DYRK1A, encodes dual-specificity
tyrosine phosphorylation-regulated kinase 1A, a serine/threonine
kinase that phosphorylates NFATc in a regulatory region, priming
NFATc for phosphorylation by CK1 and GSK3, leading to
nuclear export and inactivation [68]. Thus increased expression
of both DSCR1 and DYRK1A inhibits NFATc activation and
leads to decreased levels of nuclear NFATc [69]. Furthermore,
mice lacking NFATc2 or NFATc4 show skull and jawbone
abnormalities similar to those seen in the Down syndrome
phenotype, suggesting that inhibition of NFAT signalling by
increased DSCR1 and DYKIA makes a functional contribution to
the Down’s-syndrome phenotype [69]. Clearly these data provide
compelling evidence that NFAT signalling plays a central role
in the development of the nervous system and regulates many
of its pathways. The challenge now is to identify those genes
that are regulated by NFATc signalling in the different neuronal
subtypes and understand how NFATc can have such disparate and
apparently opposing functions that are dependent on cell type as
well as developmental stage [66]. Whether the individual NFATc
isoforms have specific functions is not known. However, the fact
that loss of individual NFATc genes does not result in any major
abnormalities and that different NFATc members can recognize
the same DNA sequence suggests that members of the NFATc
family have overlapping functions [70].
KChIP/DREAM (potassium channel interacting protein/downstream
regulatory element antagonistic modulator)
Calcium influx has extensive effects on gene expression
programmes in neurons, and the modulation is mediated by
several independent mechanisms. Perhaps the most direct effect
of calcium on regulation occurs via the transcriptional repressor
DREAM (also known as KCHIP2). DREAM is a calcium-binding
protein containing four EF-hands which bind calcium and interact
with DNA via an undetermined region that binds to a specific
sequence known as a DRE (downstream regulatory element) [71].
DREAM is abundantly expressed throughout the nervous system
in humans and mice [71,72] as well as in non-neuronal tissues
[71,73]. It binds to DNA as a tetramer and represses transcription
in a calcium- and cAMP-dependent manner. In the absence of
calcium, DREAM binds to the DRE and inhibits gene expression,
while increases in calcium permit calcium binding by DREAM,
resulting in the dissociation of the repressor from the DNA
and a consequent derepression of target genes [71]. DREAM is
regulated by alternative splicing, phosphorylation and degradation
via caspase signalling [72]. Phosphorylation via a component of
the PI3K (phosphoinositide 3-kinase) pathway is required for
DNA binding of DREAM in haematopoietic progenitor cells,
Figure 2 Interactions between DREAM and CREM/CREB integrate Ca2+ and
cAMP signalling
In the absence of calcium, DREAM binds to a DRE sequence found downstream of target
genes and represses expression. In haematopoetic cells, binding of DREAM is enhanced by
PI3K-dependent phosphorylation, although whether such a mechanism is important in the
nervous system is not known. DREAM contains four EF-hands, which bind Ca2+ and in
response to increased calcium, DREAM dissociates from DNA, resulting in de-repression
of gene expression. DREAM also interacts with the cAMP-responsive transcription factors
CREB and CREM. These interactions occur in the absence of Ca2+ and inhibit CREB and
CREM interactions with DNA, preventing cAMP-mediated transcriptional activation. Increases
in Ca2+ promote dissociation of the DREAM–CREM/CREB complex, whereas phosphorylation of
CREM promotes its interaction with DREAM and inhibits its binding to DNA.
although the candidate kinase responsible has yet to be identified
[73]. In glia, cellular localization of DREAM is modulated via
serum-response pathways. In the absence of serum, it is found
exclusively in the nucleus, where it represses expression of the
c-fos gene [74]. Upon glutamate or serum stimulation, DREAM is
relocalized to the cytoplasm and c-fos expression is de-repressed,
in turn leading to activation of a panel of c-fos target genes
[74]. Unlike in neurons, where c-fos expression is stimulated
in response to glutamate via CREB, ERK (extracellular-signal-
related kinase) and/or CaMKIV pathways, in glia it appears that
this inhibition of DREAM is the important pathway for c-fos
induction. Whether increases in calcium concentration alone or
a post-translational modification, such as phosphorylation, are
important in the inhibition and relocalization of DREAM in glia
has not been determined. Expression of DREAM also impacts
upon cAMP signalling. In the absence of calcium, DREAM inter-
acts with CREB and CREM (cAMP-responsive-element modul-
ator), preventing them from binding cAMP response elements
[75] (Figure 2). The interaction between DREAM and CREB
occurs within the kinase-inducible domain of CREB and
prevents the interaction between CREB and the co-activator CBP,
thus preventing cAMP-mediated transcriptional activation [75].
The ability of DREAM to bind DNA is also inhibited by its inter-
action with CREM, and phosphorylation of CREM in response
to cAMP signalling increases this interaction with DREAM and
potentiates de-repression of DREAM target genes [76].
DREAM is a member of a family of four calcium binding
proteins (KCHIP1– KCHIP4) that were initially characterized by
their interactions with voltage-gated potassium channels and their
ability to enhance cell-surface expression of potassium channels
and increase potassium-channel activity in a calcium-dependent
manner. Each of the KCHIPs can bind to a DRE sequence in vitro
[77], and oscillation of DRE-binding activity in the pineal gland
(whose function is important in regulating a circadian rhythm
and sleep/wake cycle) is thought to be responsible for oscillatory
expression of three genes: fra2 (Fos-related antigen), ICER
(inducible cAMP repressor) and AA-NAT (acylalkalamine N-
acetyltransferase) [77]. What regulates the rhythm of DREAM
is unknown, although the fact that mRNA and protein levels
remain constant while the levels of DRE binding to DNA fluctuate
simultaneously, suggests that a post-translational mechanism may
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Figure 3 Regulation of FOXO1 activity
FOXO1 is phosphorylated at Ser256 by phospho-Akt in response to activation of the PI3K
pathway. Phosphorylation of Ser256 creates a binding site for 14-3-3 proteins, which sequester
FOXO1 in the cytoplasm, preventing it from functioning as a transcription factor. FOXO1
is also constitutively phosphorylated by Cdk1 on Ser249. Phosphorylation of Ser249 inhibits
14-3-3 binding, thus allowing FOXO1 to enter the nucleus and activate expression of genes
such as those coding for Fas ligand (Faslg) and Bim (Bcl2l11), proteins which promote
apoptosis. Neuronal activity inhibits Cdk1 activity and promotes cytoplasmic sequestration
of FOXO1 and neuronal survival. An animated version of this Figure can be found at
http://www.BiochemJ.org/bj/414/0327/bj4140327add.htm.
be responsible. The diverse functions of DREAM as both a
potassium-channel modulator and a transcription factor do not
appear to have any co-regulatory connections, and so far the
data are consistent with separate nuclear and cytoplasmic roles
for DREAM. Whereas the binding of calcium promotes the loss
of DREAM from DNA, it is not known whether it leaves the nu-
cleus. Furthermore, interactions between DREAM and potassium
channels seem to be constitutive, suggesting that the cytoplas-
mic pool of DREAM would not have the opportunity to translocate
to the nucleus. Whether DREAM really does have two distinct
functions and the mechanisms by which DREAM is partitioned
between the nucleus and cytoplasm within a given cell remain
undetermined. However, increases in the expression of the A-
type (Kv1 family) potassium channels could potentially increase
the cytoplasmic pools of DREAM and result in decreased nuclear
DREAM with the consequence of a de-repression of DREAM
target gene expression. Conversely, diminished A-type potassium
channel expression (either in response to normal signals or in
knockout mouse models) would have the opposite effect and could
potentially decrease the expression of DREAM target genes.
GENE EXPRESSION CHANGES IN RESPONSE
TO NEURONAL INACTIVITY
Excessive neuronal activity results in glutamate excitotoxicity and
cell death. However, some neuronal activity and NMDA receptor
activation is important for neuronal survival (reviewed in [78]).
Recently the transcription factor FOXO1 (forkhead box O1) has
been implicated in promoting cell death in the absence of neuronal
activity [79]. Deprivation of neuronal activity activates the protein
kinase Cdk1 (cyclin-dependent kinase 1) which phosphorylates
FOXO1 at Ser249 (Figure 3) [79]. Phosphorylation at this residue
prevents the interaction of FOXO1 with 14-3-3 proteins (which
otherwise sequester it in the cytoplasm), leading to the nuclear
accumulation of FOXO1. In the nucleus, FOXO1 acts as a
transcriptional activator and increases expression of pro-apoptotic
target genes such as Fslg (Fas ligand) and Bcl2l11 (Bim), which
promote neuronal cell death [79]. FOXO1 is also regulated
through the PI3K pathway and is phosphorylated by activated Akt
(protein kinase B) at Thr24, Ser256 and Ser319 [80]. Phosphorylation
at these sites promotes interaction of FOXO1 with 14-3-3 proteins
and is required for sequestration of FOXO1 in the cytoplasm.
Thus PI3K signalling inhibits FOXO1 activity, and this is one of
many mechanisms by which PI3K activity promotes neuronal cell
survival, some others being the phosphorylation and inactivation
of BAD (Bcl-2 antagonist of cell death) [81] and the activation of
nuclear factor κB [82].
Epigenetic regulation
Regulation of gene expression via epigenetic mechanisms is im-
portant during normal development, providing a potential mech-
anism for cellular memory and the inheritance of gene-express-
ion-pattern information during mitosis. DNA methylation is the
prototypical epigenetic marker and is required for repressing
gene transcription, X-inactivation, genomic imprinting and
maintaining chromosome stability. Several neurological disorders
arise in response to mutations in the proteins that are involved
in methylating DNA or that are recruited to methylated DNA,
suggesting that appropriate DNA methylation within the nervous
system is vital to stave off disease. It has been a long-held belief
that DNA methylation patterns, once set during development, are
maintained throughout the life of the organism and provide a
permanent storage mechanism for specific cell lineages. More
recent data, however, has provided evidence that suggests DNA
methylation may be dynamic and that removal of methylation
marks could play an important role in plasticity and normal
functioning of the nervous system. Methylated CpG dinucleotides
contribute to gene repression by inhibiting the binding of specific
transcription factors [83] or recruit proteins that contain methyl-
CpG-binding domains and act as transcriptional repressors [84].
Fragile X syndrome, the most common form of inherited mental
retardation, affecting 1 in 1000 individuals, is the result of DNA
methylation of an expansion of CGG sequence within the 5′
untranslated region of FMR1 [FMRP (fragile X mental retard-
ation protein) gene]. FMR1 is an RNA-binding protein that plays
a role in regulating translation. FMRP associates with polyribo-
somes and inhibits translation of some mRNAs in neurons
[85,86]. DNA methylation of the FMR1 gene silences its express-
ion, leading to increased translation in areas of the cerebral
cortex [87,88]. Mutations in MeCP2, which binds to methylated
CpG dinucleotides and represses transcription [89], cause Rett
syndrome [90]. This progressive neurodevelopmental disorder
that is linked with mental retardation, almost exclusively affects
females. In normal development, MeCP2 expression increases as
neurons differentiate prior to synaptogenesis [91], whereupon it
translocates to the nucleus [92]. Once in the nucleus, MeCP2
represses transcription [93], either by recruiting HDAC (histone
deacetylase) activity (via the co-repressor mSin3) [94,95], his-
tone H3 lysine 9 methylase activity [96], interacting directly with
chromatin [97] or remodelling chromatin, possibly via its interac-
tion with the Brahma chromatin-remodelling complex [98], res-
ulting in a more compact chromatin structure [99]. Three specific
mutations within the MeCP2 gene, which lead to mental retard-
ation, have been shown to disrupt the binding of MeCP2 to
ATRX (α-thalassaemia/mental retardation, X-linked) rather than
affecting its binding to DNA directly [100]. The precise function
of ATRX in vivo is unclear, although it can interact with a num-
ber of chromatin-binding proteins and, in vitro, possesses
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Figure 4 Control of MeCP2 gene regulation
In neuronal progenitor cells Calb1 and Bdnf promoters are repressed by the transcriptional repressor REST. Neuronal differentiation results in the loss of REST expression, but the co-repressors
CoREST (not shown) and MeCP2 remain bound at the promoters containing methylated DNA and repression of Calb1 and Bdnf is maintained. Neuronal activity stimulates the expression of Bdnf as
a result of loss of MeCP2, owing to its phosphorylation, which results in cytoplasmic sequestration of MeCP2 and/or demethylation of DNA, which in turn removes the MeCP2 binding site. It is not
clear why neuronal activity can result in loss of MeCP2 from the Bdnf promoter, but not the Calb1 promoter; presumably other, as yet undetermined, factors are also required.
chromatin-remodelling activity [101]. Mutations in the gene
also lead to mental retardation, suggesting that there may be a
commonality in the mechanism that leads to these neurological
defects. Although it is widely expressed throughout the body,
deletion of MeCP2 in the brain [102] or specifically in neurons
[103] results in the neurological symptoms that mimic Rett
syndrome. Encouragingly this neurological disorder can be
rescued by artificially induced expression of MeCP2, even in
mature animals [104]. However the level of MeCP2 expression is
likely to be critical, because just as too little MeCP2 is deleterious,
so is too much. Duplication of the MeCP2 gene in human males
is associated with progressive neurodevelopmental disorders and
mental retardation [105], whereas in mice, a 2-fold increase in
expression results in neurological abnormalities [106].
Identifying the specific genes that are affected by MeCP2
abnormalities should provide some understanding of the
development of neurological disorders. A genome-wide screen
for gene expression changes in the brain due to the loss of
MeCP2 resulted in only very modest differences being noted
[107]. Several MeCP2 target genes have been uncovered, the best
studied of which is BDNF [108,109]. MeCP2 has been shown
to be recruited to promoter III of the mouse Bdnf gene, where it
represses expression of BDNF. Upon membrane depolarization,
MeCP2 is phosphorylated by a CaMKII-dependent mechanism
and is released from the Bdnf promoter, resulting in de-repression
of BDNF [22,108,110]. Such findings would suggest that patients
with Rett syndrome are likely to have increased expression of
BDNF. However, mice lacking MeCP2 show decreased levels
of BDNF and overexpression of Bdnf in these mice increased
locomotor activity and lifespan [111]. As BDNF levels are known
to be stimulated by neuronal activity, this apparent discrepancy
in BDNF levels in MeCP2-null mice may be a secondary effect
due to altered neuronal activity in MeCP2-null mice, perhaps by a
compensatory repressive mechanism via other factors such as the
complex of SUV39H1, a methyltransferase, with HP1 (hetero-
chromatin protein 1) or a reflection of altered promoter usage.
Interestingly MeCP2 is also recruited to the Calb1 promoter
in neural stem cells, though membrane depolarization does not
appear to lead to loss of MeCP2 from Calb1 in neural stem
cells even under the same conditions that lead to loss of MeCP2
from the Bdnf gene [22]. The selective loss of MeCP2 from
the Bdnf promoter may be due to a loss of 5-methylcytosine
that has been observed at the Bdnf promoter in response to
membrane depolarization (Figure 4) [109]. In vivo, MeCP2 is
also recruited to the promoters of Sgk (serum glucocorticoid-
inducible kinase 1) and Fkbp5 (FK506-binding protein 5), two
genes whose expression is increased in MeCP2-null mice, linking
MeCP2 with the stress-response pathway in the brain. Together
the results suggest that MeCP2 functions as a modulator of gene
expression in response to neuronal activity. Such a model might
explain why no significant structural changes are seen in brains
of mice lacking MeCP2 compared with normal animals, why Rett
syndrome presents as a progressive neurodevelopmental disorder
and why only subtle changes in global gene expression profiles
have been found.
Transient DNA methylation
DNA methylation mediates long-term storage of gene-expression
information throughout the life of the organism. It would make
sense that similar mechanisms could be used in the encoding of
memories, some of which are stored and are able to be recalled
many years later. Traditionally, however, in differentiated tissues,
DNA methylation was considered to be a static, rather than
dynamic, modification. It was believed that once a DNA methyl-
ation pattern was set and the cells differentiated, that methylation
pattern would be permanent. However, it has recently come to light
that DNA methylation patterns in the developed brain may in fact
be dynamically regulated. DNA is methylated by DNMTs (DNA
methyltransferases), which catalyse the addition of a methyl group
at the C-5 position of cytosine residues in CpG dinucleotides.
Consistent with this idea, DNMTs are expressed at high levels
in developing tissue but decline during differentiation and are
expressed at only low levels in differentiated tissue. The brain,
however, is somewhat exceptional in that it continues to express
high levels of DNMT mRNA into adulthood, and some previous
experiments have shown that expression of DNMT is dynamically
regulated and that its function is important for synaptic plasticity
[112].
In acutely dissociated hippocampal slices from mouse brain,
pharmacological inhibition of DNMTs using either 5-aza-2-
deoxycytidine or zebularine resulted in an increase in the level
of unmethylated DNA in a CpG-rich region of the Reelin
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promoter [113]. The effect was rapid, being observed after a
40 min incubation, and correlating with this loss of methylated
DNA was a concomitant loss of LTP [113]. Other groups have
shown that incubation of dissociated mouse hippocampal neurons
with DNMT inhibitors results in a decrease in the frequency
of mEPSCs (miniature excitatory postsynaptic currents). Such
currents are important for controlling neuronal excitability and
a decrease in mEPSCs would be predicted to reduce neuronal
network activity [114]. In the absence of DNMT inhibitors,
synaptic activity alone through NMDA receptors was sufficient
to reduce DNA methylation and frequency of mEPSCs [114],
suggesting a negative feedback loop and homoeostatic control
of synaptic activity. Furthermore the decrease in mEPSCs
required MeCP2, as DNMT inhibition had no effect in neurons
from MeCP2-knockout mice, which show constitutively low
frequency of mEPSCs [115]. Together these results suggest that
one function of MeCP2 in vivo is to limit synaptic transmission
by repressing genes that show increased DNA methylation in
response to synaptic activity. In rats, DNMT mRNA is up-
regulated in the hippocampus in a behavioural model of learning
and memory known as fear conditioning [116]. Inhibition of
DNMT during this process using either 5-aza-2-deoxycytidine or
zebularine blocked memory formation, suggesting that an increase
in DNA methylation (and thus an increase in the repression of
specific genes) is important in this process [116]. In response to
fear conditioning, methylation of the PP1 (protein phosphatase
1) gene, whose protein product is know to suppress memory
formation [117], was increased and the mRNA levels of PP1 de-
clined. Inhibition of DNMT prevented both the increased PP1
methylation in response to fear conditioning and the decrease in
PP1 mRNA levels, consistent with a role for DNA methylation
in repressing gene expression [116]. In contrast with the PP1 gene,
Reelin (which encodes a protein that enhances synaptic plasticity
[118]) showed a reduction in the level of methylated DNA and an
increase in Reelin mRNA in the CA1 hippocampal region, with
both of these effects being potentiated by the DNMT inhibitor 5-
aza-2-deoxycytidine. As in the in vitro hippocampal-slice model,
DNA methylation changes in the adult rat brain are very rapid
and changes in DNA methylation levels and the effects of DNMT
inhibition are seen within 1 h of the fear-conditioning response
[116].
The existence of an activity that demethylates DNA is still
somewhat controversial and, at least for some, a convincing
demonstration of its molecular identity is still eagerly anticipated.
The observations that high levels of DNMT mRNA are
present in the brain and that synaptic activity correlates with
increased levels of methylated DNA and reduced mRNA of
some genes, coupled with the ability of at least two DNMT
inhibitors to prevent appropriate memory formation, provides
some compelling evidence that de novo DNA methylation is
important in synaptic plasticity. If the addition of methyl groups
to the DNA at some genes is an important mechanism in learning
and memory, then there must be some mechanism to remove
these marks, otherwise there would be a lifetime’s accumulation
of methylated DNA in our brains, eventually leading to a loss of
plasticity in response to altered synaptic input. Several candidates
for a DNA demethylase have been proposed. Initially, MBD2
(methyl-CpG-binding domain protein 2) was identified as having
DNA demethylase activity [119] via an oxidative demethylation
mechanism based on GC–MS of the components in a DNA
demethylase assay [120]. However, other groups have struggled
to replicate this demethylase activity of MBD2 [121,122]. In
Xenopus laevis the DNA repair protein Gadd45a (growth arrest
and DNA-damage-inducible 45 alpha) was proposed to stimulate
DNA demethylation by a DNA-repair process [123]. However,
such activity may be species-specific, since the human Gadd45a
does not appear to promote DNA demethylation in HEK-293
cells [124]. Most recently a mechanism involving deamination of
methylated cytosine residues by DNMT3a/b followed by DNA
repair by TDG (thymine-DNA glycosylase) has been proposed
[125]. This last set of results suggests that DNMTs may promote
both DNA methylation and demethylation. One prediction from
this hypothesis would be that DNMT inhibitors would inhibit
DNA methylation and demethylation. However, to date, only
reduction in DNA methylation has been observed following
DNMT inhibition. Though each of these studies has examined
DNA demethylation in non-neuronal proliferating cells, it is likely
that mechanisms of DNA demethylation would be the same in
neurons. In fact, as proliferating cells would be expected to have
relatively high levels of DNMT expression, the relatively high
levels of DNMT in the nervous system would make this an
attractive candidate for a DNA demethylase. Given the current
interest and recent progress in this area, a more consensual opinion
should hopefully emerge in the near future.
Histone modifications
In eukaryotes, DNA is wrapped around histone octamers,
consisting of two copies each of of the histones H2A, H2B, H3
and H4 to form chromatin. Though originally thought to be a
means of packaging a large amount of DNA into a relatively
small nucleus, it has become clear that changes in the post-transl-
ational modifications of histones are also important in regulating
transcription. The modifications include acetylation, methylation,
phosphorylation and ubiquitination. Enzymes that add or remove
these modifications play important roles in regulating gene
expression, and the addition and removal of all of these marks is
dynamic. Furthermore, multiple states of methylation can occur
on either arginine or lysine residues (mono- or di- for arginine and
mono-, di- or tri- for lysine). Given the huge potential for different
combinations of histone modifications, it has been proposed that
the pattern of modifications could function as a code that could
provide regulatory information for the genes encoded within the
surrounding DNA [126]. Although such a code, if it exists, has
yet to be deciphered, much has been learnt recently regarding the
association of specific histone modifications with gene-regulatory
events.
Acetylation
High levels of histone acetylation are associated with transcrip-
tionally active DNA, whereas hypoacetylated histones are asso-
ciated with transcriptionally repressed DNA [127,128]. Histones
are acetylated by HATs such as CBP and p300 [39] and the acetyl
groups removed by HDACs such as HDAC1 [129]. Mutations in
the histone acetyltransferase CBP are the cause of Rubenstein–
Taybi syndrome, a condition with clinical features that include
facial abnormalities and mental retardation, implicating HAT
activity as vital for normal cognitive function [130]. In the adult
brain, regulation of acetylation and deacetylation of histones plays
an important role in synaptic plasticity and in the response to
epileptic insults, ischaemia and anti-psychotic drugs [131–133].
Kainic acid-induced seizures in rats lead to increased
expression of the transcriptional repressor REST in hippocampal
neurons [134]. REST represses transcription by recruiting
multiple chromatin-modifying enzymes, including HDACs [30],
and increased expression of REST in response to pilocarpine-
induced seizures in rats correlates with a reduction in the acetyl-
ation levels of histone H4 at the Gria2 (glutamate receptor,
ionotropic, AMPA 2) promoter and decreased expression of
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GluR2 (glutamate receptor subunit 2) [131]. Reduction in Gria2
mRNA could be prevented by pre-administration of the HDAC
inhibitor trichostatin A, indicating that the observed deacetylation
is required for gene repression. Changes in histone acetylation
levels in response to seizures are promoter-specific and can
increase as well as decrease. BDNF is transcribed from four
independent promoters (I, II, III and IV), and expression of
Bndf increases in response to seizure activity [135]. Like
Gria2, Bndf is also repressed by REST via an RE1 (repressor
element 1) sequence within promoter II [136]. Seizure activity
results in increased H4 acetylation levels at promoter I and
decreased H4 acetylation levels at promoter IV [131], though
the sum of these changes are an overall increase in Bndf mRNA
[135]. REST expression is also increased in the hippocampus
in response to global ischaemia [132] and results in repression
of Gria2 mRNA in one type of hippocampal neuron (the CA1
pyramidal neuron), which subsequently die, owing to the
increased calcium entry via GluR2 lacking AMPA receptors
[132]. Increased REST levels also repress the expression of Mor1
(μ opioid receptor gene), which is highly expressed in basket
cells and interneurons within the CA1 hippocampal region [137].
Repression of the Mor1 gene is associated with deacetylation
of histones H3 and H4 and dimethylation of H3 lysine 9 at
the Mor1 promoter, presumably a result of the recruitment of
HDACs and the H3 lysine 9 methyltransferase G9a by REST
[137]. Unlike repression of GluR2, which promotes neuronal cell
death, repression of Mor1 promotes cell survival. Mor1 activation
inhibits the release of the inhibitory neurotransmitter GABA by
interneurons. Reduction of Mor1 would therefore be predicted
to result in increased GABA release, reduced synaptic activity
and would be opposed to excitotoxicity mediated by excessive
glutamate release. Additonally, anti-psychotic drugs such as
cocaine stimulate acetylation of H3 and H4 in the striatum [133].
Histone deacetylation has been implicated in the pathogenesis
of several neuronal diseases, and inhibitors of HDACs have
been successfully used to reverse gene repression in animal
models of human diseases such as Huntington’s disease [138],
neurodegeneration [139] and Rubinstein–Taybi syndrome [140].
Despite the fact that these HDAC inhibitors are non-specific and
will inhibit all HDAC activity within the brain, these inhibitors
do not appear to increase expression of all genes, nor do they
have widespread deleterious side-effects. Thus these inhibitors
are currently very promising for use in the treatment of a range of
human disorders that result in impaired cognition (for a discussion
on therapeutic use of HDAC inhibition, see [141]).
Methylation
Unlike histone acetylation, the effects of histone methylation are
dependent on the specific residue that is modified. For example,
methylation of H3K4 (H3 Lys4) is associated with gene activation,
while methylation of H3K9 and H3K27 (H3 Lys9 and Lys27) are
associated with gene repression. Initially, methylation of lysine
residues on histones was thought to be irreversible. However,
in 2004, Yang Shi’s laboratory identified the first lysine-specific
demethylase, LSD1 [142], and soon other LSDs were identified
[143]. Several independent observations have highlighted the
importance of histone methylation in the nervous system.
Loss of the transcriptional repressor REST is an important step
in the differentiation of neural stem cells to neurons [22,24,25].
Two of the co-repressors recruited by REST, G9a and LSD1,
alter histone methylation levels [29,142]. LSD1 demethylates
H3K4, thus removing a chromatin mark associated with active
transcription, while G9a dimethylates H3K9 and H3K27 [144],
thus adding chromatin marks associated with gene repression.
One of the co-repressors present in the complexes associated with
REST is the chromatin-associated high-mobility-group protein
BRAF35 (BRCA2-associated factor 35) [145]. BRAF35 is highly
expressed in proliferating cells but not in differentiated neurons.
During differentiation of neural progenitor cells, expression of
the BRAF35 family member iBRAF (inhibitor of BRAF35) is
induced and inhibits REST-mediated repression, at least in part,
by recruitment of the H3K4 methylase MLL (mixed-lineage
leukaemia) [146]. Importantly, MLL is able to trimethylate H3K4
and, once trimethylated, H3K4 is resistant to demethylation by
LSD1, which, because of its mechanism of catalysis, is only able
to use mono- or di-methylated H3K4 as a substrate [142].
JARID1C [Jumonji, AT-rich interactive domain 1C; also known
as SMCX (Smcy homologue, X-linked)] is a histone demethylase
specific for H3K4 that will demethylate tri- or di-methylated
H3K4 to monomethylated H3K4 [147]. JARID1C is highly
expressed in the brain of mice and mutations in JARID1C result in
X-linked mental retardation in humans [148]. In zebrafish (Danio
rerio) brains, loss of JARID1C results in increased neuronal
cell death, whereas in rodent neurons knockdown of JARID1C
decreases dendrite length [147], suggesting that JARID1C mut-
ations in humans may result in reduced neuronal numbers and/or
altered neuronal morphogenesis. Huntington’s disease is also
associated with altered neuronal histone methylation patterns.
Post-mortem brains from Huntington’s-disease patients show
increased levels of H3K9 methylation, and a mouse model of
Huntington’s disease shows elevated H3K9 methylation and
increased levels of the H3K9 methyl transferase ESET [ERG
(ets-related gene)-associated protein with SET (suppressor of
variegation, enhancer of zest and trithorax) domain] [149]. The
increased ESET expression observed in these mutant mice may
be the result of increased Sp1 and/or Sp3 activity or sequestration
of CBP by the mutant Huntingtin protein. In support of the
latter hypothesis, mice lacking one allele of the CBP gene show
increased expression of the histone methyltransferase ESET, due
to increased activity of Ets-2, and high levels of H3K9 methylation
in neurons [150].
Phosphorylation
Histone H3 can be phosphorylated on Ser10 and Ser28. Phos-
phorlyation of H3 has been associated with mitotic chromatin con-
densation and also with highly active gene transcription [151,152].
In neurons, phosphorylation of H3 is clearly not associated with
mitosis, but does seem to be an important component of responses
in gene expression evoked by synaptic activity. Stimulation of
neuronal activity by injection of either dopamine, muscarinic
or glutamate receptor agonists into mouse brains resulted in a
transient H3 Ser10 phosphorylation in the dentate gyrus and CA3
regions of the hippocampus, which peaked within 1 h and was
lost after 3 h [153]. Phosphorylation of H3 occurred in the same
neurons as phosphorylation of ERK, which is thought to be at least
partly responsible for inducing H3 phosphorylation. Furthermore
the time course of H3 phosphorylation correlated with the
induction of expression of the immediate early genes c-fos and
MKP-1 and MKP-3 [MAPK (mitogen-activated protein kinase)
phosphatases 1 and 3] [153]. Glutamate treatment of cultured
striatal neurons induces c-fos and c-jun mRNA expression via
induction of ERK and its downstream target mitogen- and stress-
activated kinase-1 (MSK1) [154]. MSK1 directly phosphorylates
histone H3 Ser10 and Ser28 [155] and inhibition of this phos-
phorylation is sufficient to prevent induction of c-fos expression
by glutamate, suggesting that this is the regulatory step [154]. In a
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mouse model of Huntington’s disease, striatal neurons were found
to express low levels of c-fos mRNA, lack MSK1 activity, and
phosphorylation of histone H3 at the c-fos promoter did not occur
in response to activation of the ERK pathway [156]. Analysis of
post-mortem brain samples from Huntington’s patients showed a
reduced level of MSK-1 in the striatum, but not the cerebral cortex,
suggesting that the findings in the mouse model are relevant to the
human disease [156]. As described above, increased acetylation
of histones is correlated with transcriptional activation. It has been
suggested that phosphorylation of H3 Ser10 enhances acetylation
of H3, and several histone acetyltransferases have a higher affinity
for a phosphorylated H3 template [157]. It is not clear how H3
phosphorylation mediates transcriptional activation, though its
ability to promote H3 acetylation would be one potential mech-
anism. However, stimulation of neuronal activity did not appear
to increase the global level of acetylated H3 Lys9 or Lys14, nor the
levels at the c-fos promoter, which were already high in hippo-
campal neurons [153]. This suggests that, although phosphoryl-
ation may stimulate acetylation of H3, there must be another
additional mechanism by which phosphorylated H3 activates tran-
scription. Potentially, phosphorylated H3 could stimulate acetyl-
ation of histone H4, or the phospho-acetylated H3 tail may provide
a platform to recruit other transcriptional activator proteins.
There still remains much to be uncovered regarding the role
of histone modifications in regulating neuronal gene expression.
Owing to technical limitations, most of what we know about the
role of histone modification has come from studying homogene-
ous cell populations, usually yeast or immortalized mammalian
cell lines. The advantage of these systems is that histone
modifications can be easily perturbed using chemical treatments
that inhibit specific histone-modifying enzymes and thus allow
the preparation of large amounts of chromatin for biochemical
analysis. By contrast, the brain not only contains a heterogeneous
mix of cell types, but the neurons themselves are a phenotypically
diverse population with individual gene-expression profiles.
Recent advances in techniques such as ChIP, mean that fewer
cells than ever before are required in order to analyse histone
modification. For this reason, it will now be possible to interrogate
histone modification changes in neuronal specific subtypes, and
these kinds of studies are expected to yield interesting new data
in the near future.
MICRORNAS AND NEURONAL GENE EXPRESSION
MicroRNAs are short RNAs approx. 22 nucleotides in length that
down-regulate expression of proteins by either inhibiting transl-
ation or promoting mRNA degradation. (While the consensus
view is that microRNAs result in down-regulation of mRNA
and/or protein levels of their targets, recent evidence suggests that
at least some microRNAs which repress expression in prolifer-
ating HeLa and HEK-293 cells can activate expression of their
target mRNAs upon cell-cycle arrest [158]. This has led to
the suggestion that microRNA function is cell-cycle-dependent.
However, whether some microRNAs can also activate expression
in neurons has not been tested, and to date all of the experimental
evidence supports a role for repression only by microRNAs in
neurons.) The biogenesis and function of microRNAs in the brain
was recently reviewed [159], and here we will focus on some
recent examples which provide some insight into the role of
microRNAs in controlling neuronal function by contributing to
specific gene-regulatory networks.
The microRNA mir-124 was originally identified as a
microRNA specifically expressed in the brain [160,161] and
later was shown to negatively regulate the expression of
Figure 5 microRNA feedback loops in neuronal gene expression
(a) REST can be alternatively spliced, producing a full length-protein (REST) or C-terminal
truncated protein found exclusively in neurons (N-REST) that is non-functional. In non-neuronal
cells and neural stem cells, REST represses the microRNA mir-124. Loss or inhibition of REST
results in increased expression of mir-124, which inhibits the expression of the splicing regulator
PTBP1, resulting in increased expression of the related protein PTBP2. PTBP2 promotes splicing
of neuronal-specific isoforms, which would lead to increased levels of N-REST and diminished
levels of REST, forming a double-negative-feedback loop driving neuronal differentiation.
(b) One of the target genes of CREB is the microRNA mir-132 whose expression is elevated in
response to activation of the CREB signalling pathway. mir-132 inhibits expression of MeCP2 so
activation of CREB would result in reduced MeCP2. Paradoxically, reduced MeCP2 levels result
in reduced levels of BDNF. Like activated CREB, BDNF also activates expression of mir-132 so
reduced BDNF leads to reduced mir-132. This network produces a homoestatic loop of mir-132
- MeCP2 and BDNF expression levels which is regulated by CREB signalling. Most likely such
regulatory loops as this exist because it allows a fast response in expression levels of the
components in response to an external stimulus, in this case CREB activation.
many non-neuronal genes [162] and play an important role
in neuronal differentiation [163]. One of the targets for
mir-124 is PTBP1 (polypyrimidine-tract-binding protein 1),
a regulator of mRNA splicing that represses production of
neuronal specific mRNA isoforms. By inhibiting PTBP1, mir-124
enhances the production of neuronal-specific transcript isoforms
and promotes neuronal differentiation [164,165]. Interestingly
expression of mir-124 is repressed by the transcriptional repressor
REST [163,166]. REST is expressed at high levels in non-
neuronal cells, and down-regulation of REST is a requirement
for neuronal differentiation [22]. At least some neurons do express
low levels of REST, and an alternatively spliced form of REST is
present in neurons, the function of which is unclear (see [30] for
a discussion on the alternatively spliced form of REST). Given
that mir-124 promotes splicing of neuronal-specific transcripts,
then induction of mir-124 could inhibit the function of REST
by promoting the incorporation of the neuronal-specific exon of
REST, giving rise to a truncated protein that shows diminished
repressing ability. This would thus provide a double negative-
feedback loop between REST and mir-124 (Figure 5a). Such a
loop would produce a bistable switch with the potential to provide
for robust changes in mir-124 expression levels in response to a
modest initiation signal (Figure 5a). Other microRNAs important
for neuronal development include mir-133b, which regulates the
maturation and function of midbrain dopaminergic neurons as
part of a negative feedback loop with the transcription factor
Pitx3 (paired-like homeodomain transcription factor 3) [167].
Not only are microRNAs important during development, but
they also have a function in the mature nervous system and con-
tribute to the changes in gene expression that underlie neuronal
plasticity. One such microRNA is mir-132, which is expressed
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in neurons and whose levels are increased via activation of the
CREB signalling pathway [168]. One of the targets of mir-132
is MeCP2, and inhibition of mir-132 in cortical neurons using
an antisense oligonucleotide resulted in increased MeCP2 protein
levels, but had no effect on MeCP2 mRNA levels [169]. Despite
MeCP2 being a well-characterized repressor of gene expression,
surprisingly, its increased level is accompanied by an increase
in BDNF expression (as observed in MeCP2 null mice; see
‘Epigenetic regulation’ subsection above). Whether the increase
in BDNF is a direct or indirect effect of MeCP2 or a secondary
effect of mir-132 on another target gene is not known. Increases
in BDNF have been shown to result in increased expression of
mir-132 [168], suggesting that mir-132, MeCP2 and BDNF form
a homoeostatic loop where increases in BDNF would lead to in-
creased mir-132 levels that reduce MeCP2 protein, leading to
reduced BDNF (Figure 5b). BDNF antagonizes the function of
another microRNA, mir-134, which is expressed in neurons and
localized specifically to dendritic spines [170]. mir-134 decreases
the size of dendritic spines by inhibiting translation of the
Lim (Lin11, Isl-1 and Mec-3)-domain-containing protein Lmtk1
(lemur tyrosine kinase 1). Stimulation of the neurons with BDNF
results in the movement of Lmtk1 mRNA to the polysomes and
relieves inhibition by mir-134. Although the exact mechanism
of relief by BDNF is unclear, intriguingly it does not seem to
require the dissociation of mir-134 from the Lmtk1 3′-untranslated
region [170].
CONCLUSIONS
Not only is the brain a mixture of cell types, namely neurons,
astrocytes and glia, but, additionally, the neurons themselves
encompass a wide range of phenotypes, each of which has a
unique gene-expression profile. As a further layer of complexity,
the gene-expression profiles in each neuron are very dynamic
and exquisitely responsive to synaptic activity. Thus each neuron
within the brain has the potential to possess a unique set of
chromatin modifications and gene-expression profile. Currently
many of the tools available to study the control of gene
expression require starting material from a large number of
ideally homogeneous cells. Thus, although great strides have
been made in elucidating mechanisms which involve post-
translational modifications of chromatin proteins in non-neuronal
cells, providing such detailed information with regard to neurons
has thus far been technically challenging. Recent advances in
ChIP for relatively small numbers of cells [171,172] should help
progress in this area, perhaps in combination with methods to tag
and isolate specific subpopulations of neurons [173,174].
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